X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19747) 19747
Magazine Article (155) 155
Newsletter (64) 64
Book Chapter (25) 25
Newspaper Article (19) 19
Book / eBook (13) 13
Reference (8) 8
Book Review (7) 7
Transcript (6) 6
Dissertation (4) 4
Conference Proceeding (3) 3
Publication (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15080) 15080
sulfonamides - therapeutic use (12665) 12665
male (8098) 8098
female (6978) 6978
animals (5171) 5171
middle aged (4733) 4733
sulfonamides - pharmacology (4586) 4586
adult (3888) 3888
aged (3524) 3524
pharmacology & pharmacy (3083) 3083
sulfonamides - administration & dosage (2884) 2884
sulfonamides - adverse effects (2787) 2787
treatment outcome (2550) 2550
sulfonamides (2130) 2130
celecoxib (2129) 2129
oncology (1902) 1902
mice (1859) 1859
pyrimidines - therapeutic use (1839) 1839
drug therapy, combination (1601) 1601
rats (1551) 1551
cancer (1254) 1254
dose-response relationship, drug (1246) 1246
analysis (1244) 1244
rosuvastatin calcium (1229) 1229
sulfanilamides (1130) 1130
adolescent (1110) 1110
double-blind method (1106) 1106
care and treatment (1089) 1089
cell line, tumor (1084) 1084
drug therapy (1080) 1080
expression (1072) 1072
anti-bacterial agents - therapeutic use (1054) 1054
research (1052) 1052
therapy (1043) 1043
antineoplastic agents - therapeutic use (1025) 1025
fluorobenzenes - therapeutic use (1018) 1018
pyrazoles - therapeutic use (1013) 1013
aged, 80 and over (1011) 1011
time factors (1000) 1000
apoptosis (964) 964
sulfonamides - pharmacokinetics (960) 960
antihypertensive agents - therapeutic use (943) 943
medicine, general & internal (937) 937
efficacy (923) 923
indoles - therapeutic use (922) 922
sulfonamides - chemistry (910) 910
child (897) 897
cardiac & cardiovascular systems (896) 896
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (868) 868
anti-inflammatory agents, non-steroidal - therapeutic use (855) 855
biochemistry & molecular biology (828) 828
disease models, animal (807) 807
clinical trials as topic (792) 792
medicine & public health (790) 790
cyclooxygenase inhibitors - therapeutic use (780) 780
health aspects (768) 768
prospective studies (761) 761
chemistry, medicinal (727) 727
safety (718) 718
risk factors (706) 706
apoptosis - drug effects (682) 682
mutation (682) 682
abridged index medicus (677) 677
research article (657) 657
antineoplastic agents - pharmacology (642) 642
proteins (638) 638
administration, oral (630) 630
hypertension, pulmonary - drug therapy (628) 628
cell biology (624) 624
hiv infections - drug therapy (612) 612
retrospective studies (611) 611
rats, sprague-dawley (609) 609
pharmacology/toxicology (602) 602
inflammation (600) 600
young adult (599) 599
pharmacokinetics (594) 594
clinical trials (589) 589
nonsteroidal antiinflammatory drugs (589) 589
pyrazoles (582) 582
double-blind (578) 578
dosage and administration (577) 577
drugs (575) 575
melanoma - drug therapy (575) 575
inhibition (570) 570
rosuvastatin (565) 565
medicine (553) 553
drug synergism (549) 549
drug interactions (547) 547
melanoma (544) 544
activation (543) 543
pyrazoles - pharmacology (543) 543
randomized controlled trials as topic (542) 542
follow-up studies (539) 539
medicine, research & experimental (537) 537
antineoplastic combined chemotherapy protocols - therapeutic use (533) 533
urology & nephrology (531) 531
bosentan (529) 529
inhibitors (528) 528
internal medicine (527) 527
survival (525) 525
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17583) 17583
German (936) 936
French (516) 516
Italian (267) 267
Japanese (199) 199
Spanish (191) 191
Russian (167) 167
Chinese (94) 94
Polish (77) 77
Portuguese (72) 72
Swedish (46) 46
Romanian (35) 35
Norwegian (33) 33
Czech (31) 31
Hungarian (31) 31
Dutch (30) 30
Danish (26) 26
Serbian (13) 13
Bulgarian (11) 11
Hebrew (10) 10
Finnish (9) 9
Turkish (8) 8
Ukrainian (8) 8
Slovak (7) 7
Croatian (6) 6
Afrikaans (1) 1
Korean (1) 1
Lithuanian (1) 1
Thai (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
Chest, ISSN 0012-3692, 03/2016, Volume 149, Issue 3, pp. 756 - 766
Journal Article
Blood, ISSN 1528-0020, 2019, Volume 133, Issue 18, pp. 1964 - 1976
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007360
Background Benign prostatic hyperplasia (BPH) is a common condition in ageing men that may cause lower urinary tract symptoms (LUTS). Treatment aims are to... 
Piperazines | Plant Extracts | Benzilates | Adrenergic alpha‐Antagonists | Urology | Alpha‐blockers/Alpha‐1 adrenoceptors/Alpha antagonists/5‐alpha reductase inhibitors | Naphthalenes | Randomized Controlled Trials as Topic | Prostatic Hyperplasia | Urological Agents | Tamsulosin | Lower Urinary Tract Symptoms | Sulfonamides | Quality of Life | Prostatism | Benign prostatic hyperplasia | Treatment of Benign Prostatic Hyperplasia | Ethamsylate | Indoles | Pharmacologic/Medical Therapies | Medicine General & Introductory Medical Sciences | Drug Combinations | Naftopidil | Benign Prostatic Hyperplasia/Obstruction (Hypertrophy, Prostatic Hyperplasia) | Naphthalenes [adverse effects; therapeutic use] | 75 MG | EFFICACY | Prostatic Hyperplasia [complications] | STORAGE SYMPTOM | SEXUAL FUNCTION | CLINICAL PROGRESSION | MEDICINE, GENERAL & INTERNAL | OVERACTIVE BLADDER | Sulfonamides [adverse effects; therapeutic use] | Piperazines [adverse effects; therapeutic use] | ALPHA-ADRENOCEPTOR ANTAGONISTS | Adrenergic alpha-Antagonists [adverse effects; therapeutic use] | Prostatism [drug therapy; etiology] | TAMSULOSIN HYDROCHLORIDE | ALPHA-1 BLOCKERS | HEALTH-STATUS | Benzilates - adverse effects | Naphthalenes - adverse effects | Benzilates - therapeutic use | Humans | Adrenergic alpha-Antagonists - therapeutic use | Male | Prostatic Hyperplasia - complications | Prostatism - drug therapy | Urological Agents - adverse effects | Adrenergic alpha-Antagonists - adverse effects | Ethamsylate - therapeutic use | Lower Urinary Tract Symptoms - drug therapy | Lower Urinary Tract Symptoms - etiology | Ethamsylate - adverse effects | Urological Agents - therapeutic use | Prostatism - etiology | Tamsulosin - adverse effects | Tamsulosin - therapeutic use | Piperazines - therapeutic use | Piperazines - adverse effects | Indoles - adverse effects | Sulfonamides - therapeutic use | Sulfonamides - adverse effects | Indoles - therapeutic use | Plant Extracts - therapeutic use | Naphthalenes - therapeutic use | Plant Extracts - adverse effects
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2018, Volume 2019, Issue 4, p. CD004121
Background This is an updated version of the original Cochrane review published in 2014, Issue 4. Cervical intraepithelial neoplasia (CIN) precedes the... 
Uterine Cervical Neoplasms | Administration, Oral | Anti‐Inflammatory Agents, Non‐Steroidal | CANCER OF THE UTERINE CERVIX | Induction Chemotherapy | Celecoxib | Cervix | Disease Progression | Lactones | Randomized Controlled Trials as Topic | Gynaecology | Cyclooxygenase 2 Inhibitors | Sulfonamides | Gynaecological | Placebos | Medicine General & Introductory Medical Sciences | Cervical Intraepithelial Neoplasia | Sulfones | Strategies and implementation for pre‐malignant changes | Cancer | COX-2 | Sulfones [administration & dosage; therapeutic use] | Humans | Sulfonamides [administration & dosage; therapeutic use] | COLON-CANCER | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | CHEMOPREVENTIVE ACTIVITY | TRANSITIONAL-CELL CARCINOMA | Pyrazoles [administration & dosage; therapeutic use] | Female | Lactones [administration & dosage; therapeutic use] | INHIBITOR | UP-REGULATION | Uterine Cervical Neoplasms [drug therapy] | Induction Chemotherapy [methods] | DOUBLE-BLIND | Cyclooxygenase 2 Inhibitors [administration & dosage; therapeutic use] | CYCLOOXYGENASE-2 EXPRESSION | Anti-Inflammatory Agents, Non-Steroidal [administration & dosage; therapeutic use] | Cervical Intraepithelial Neoplasia [drug therapy] | Sulfones - therapeutic use | Cervical Intraepithelial Neoplasia - pathology | Cyclooxygenase 2 Inhibitors - administration & dosage | Induction Chemotherapy - methods | Cervical Intraepithelial Neoplasia - drug therapy | Uterine Cervical Neoplasms - drug therapy | Uterine Cervical Neoplasms - pathology | Celecoxib - therapeutic use | Lactones - therapeutic use | Placebos - therapeutic use | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Lactones - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Sulfonamides - administration & dosage | Sulfones - administration & dosage
Journal Article
World journal of urology, ISSN 1433-8726, 2016, Volume 35, Issue 2, pp. 179 - 188
Journal Article
Annals of internal medicine, ISSN 0003-4819, 2015, Volume 162, Issue 6, pp. 407 - 419
Journal Article
Journal Article
Journal Article